Passage BIO (PASG) Enterprise Value (2019 - 2026)
Passage BIO (PASG) posted quarterly Enterprise Value of -$33.3 million for Q1 2026, up 47.44% year-over-year from -$22.6 million in Q1 2025, and up 28.08% quarter-over-quarter from -$46.3 million in Q4 2025.
Passage BIO (PASG) Enterprise Value (2019 - 2026) Analysis & Trends
Passage BIO's Enterprise Value history runs 8 years deep, the most recent figure standing at -$33.3 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 47.44% year-over-year to -$33.3 million; the TTM figure through Mar 2026 stood at -$33.3 million (up 47.44% YoY), while the FY2025 annual figure was -$46.3 million, up 39.68% from the prior year.
- Enterprise Value for Q1 2026 stood at -$33.3 million, up from -$46.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$33.3 million in Q1 2026, with the low at -$267.1 million in Q1 2022.
- The 5-year median for Enterprise Value is -$104.5 million (2024), against an average of -$122.8 million.
- The sharpest annual moves came in 2024 and 2026: Enterprise Value jumped 32.84% in 2024, then jumped 47.44% in 2026.
- Passage BIO's Enterprise Value stood at -$189.6 million in 2022, then surged by 39.72% to -$114.3 million in 2023, then surged by 32.84% to -$76.8 million in 2024, then surged by 39.68% to -$46.3 million in 2025, then grew by 28.08% to -$33.3 million in 2026.
- Business Quant data shows PASG's Enterprise Value at -$33.3 million in Q1 2026, -$46.3 million in Q4 2025, and -$52.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Passage BIO | 14.47 Mn | 14.47 Mn | - | -24.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.20 Mn |
| Mar 31, 2026 | -33.30 Mn |
| Dec 31, 2025 | -46.30 Mn |
| Sep 30, 2025 | -52.77 Mn |
| Jun 30, 2025 | -57.63 Mn |
| Mar 31, 2025 | -63.36 Mn |
| Dec 31, 2024 | -76.76 Mn |
| Sep 30, 2024 | -84.83 Mn |
| Jun 30, 2024 | -91.77 Mn |
| Mar 31, 2024 | -104.53 Mn |
| Dec 31, 2023 | -114.29 Mn |
| Sep 30, 2023 | -132.78 Mn |
| Jun 30, 2023 | -151.48 Mn |
| Mar 31, 2023 | -167.77 Mn |
| Dec 31, 2022 | -189.61 Mn |
| Sep 30, 2022 | -213.76 Mn |
| Jun 30, 2022 | -239.25 Mn |
| Mar 31, 2022 | -267.09 Mn |
| Dec 31, 2021 | -315.77 Mn |
| Sep 30, 2021 | -354.40 Mn |